San Diego-dependent Viking Therapeutics marked by itself as a serious competitor during the weight loss drug market in February soon after revealing promising knowledge from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection As well as in March the